Navigation Links
Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010
Date:3/17/2010

QUÉBEC CITY, March 17 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, will announce its fourth quarter and full year 2009 financial and operating results before market open on Wednesday, March 24, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 888-231-8191 (North America), or 647-427-7450 or 514-807-9895 (Canada). A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Æterna Zentaris Inc.

Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Back to top
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
2. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
3. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
4. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection ... to 2026", published by MarketsandMarkets, the global market size was USD 645.4 Million ... an of CAGR of 6.2% between 2016 and 2026. ... ... , , ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
(Date:6/27/2016)... , June 27, 2016 Research and ... North America 2016-2020" report to their offering. ... North America to grow at a CAGR of ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):